# EDGAR Filing Document

**Accession Number:** 0001213809
**File Stem:** 0001437749-23-000222
**Filing Date:** 2023-1
**Character Count:** 14042
**Document Hash:** 2c416e0296ade33e7408260e773b389b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-23-000222.hdr.sgml**: 20230104

**ACCESSION NUMBER**: 0001437749-23-000222

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 55

**CONFORMED PERIOD OF REPORT**: 20230104

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230104

**DATE AS OF CHANGE**: 20230104

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** DYADIC INTERNATIONAL INC
- **CENTRAL INDEX KEY:** 0001213809
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 450486747
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-32513
- **FILM NUMBER:** 23504458

**BUSINESS ADDRESS:**
- **STREET 1:** 140 INTRACOASTAL POINTE DRIVE
- **STREET 2:** SUITE 404
- **CITY:** JUPITER
- **STATE:** FL
- **ZIP:** 33477
- **BUSINESS PHONE:** 561-743-8333

**MAIL ADDRESS:**
- **STREET 1:** 140 INTRACOASTAL POINTE DRIVE
- **STREET 2:** SUITE 404
- **CITY:** JUPITER
- **STATE:** FL
- **ZIP:** 33477

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CCP WORLDWIDE INC
- **DATE OF NAME CHANGE:** 20030110

dyai20230103_8k.htm

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM **8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**Date of Report (date of earliest event reported) :**<u>January 4, 2023</u>**

**Dyadic International, Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware**<br> (State or other jurisdiction of incorporation or organization) | **000-55264**<br> (Commission File Number) | **45-0486747**<br> (I.R.S. Employer Identification Number) |
| **140 Intracoastal Pointe Drive, Suite 404**<br> **Jupiter, **FL 33477** | **140 Intracoastal Pointe Drive, Suite 404**<br> **Jupiter, **FL 33477** | **140 Intracoastal Pointe Drive, Suite 404**<br> **Jupiter, **FL 33477** |
| (Address of principal executive offices and zip code) | (Address of principal executive offices and zip code) | (Address of principal executive offices and zip code) |
| **(**561**) **743-8333** | **(**561**) **743-8333** | **(**561**) **743-8333** |
| (Registrant's telephone number, including area code) | (Registrant's telephone number, including area code) | (Registrant's telephone number, including area code) |
| **N/A**<br> **(Former Name or Former Address, if Changed Since Last Report)** | **N/A**<br> **(Former Name or Former Address, if Changed Since Last Report)** | **N/A**<br> **(Former Name or Former Address, if Changed Since Last Report)** |

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

| |
|:---|
| Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). |
| Emerging growth company ☐ |
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ |

---

Securities registered pursuant to Section 12(b) of the Act

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, par value $0.001 per share | DYAI | The NASDAQ Stock Market LLC |

---

------

**Item 8.01. Other Events**

On January 4, 2023, Dyadic International, Inc. ("Dyadic" or the "Company") posted a presentation entitled "Next Generation Proteins for World Health" on the Company's website at <u>www.dyadic.com</u> under the "Investors" tab. On January 4, 2023, Dyadic also issued a press release announcing that senior executive management will attend the J.P. Morgan 41st Annual Healthcare Conference in San Francisco, CA. Dyadic's founder and CEO, Mark Emalfarb will be making a corporate presentation at 4:00 PM PT on January 8, 2023 at the 6th Annual BFC Global Healthcare BD and Investment Conference, San Francisco, CA. Mr. Emalfarb will also be participating on the opening panel, which is scheduled at 9:15-10:15 AM PT.

The presentation highlights the recent advancements Dyadic has made with its C1-cell protein expression platform including the initiation of its first in human Phase 1 program for an antigen expressed in the C1 platform, with the trial expected to begin in early January 2023.

Representatives of Dyadic will use the presentation in industry conferences, investor conferences and investor meetings from time to time. A copy of the press release is filed as Exhibit 99.1 and a copy of the presentation is also attached hereto as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

---

| | |
|:---|:---|
| **Item 9.01 Financial Statements and Exhibits** | **Item 9.01 Financial Statements and Exhibits** |
| (d) Exhibits |  |
| The following exhibit is being furnished herein: | The following exhibit is being furnished herein: |
| **Exhibit**<br> <u>**Number**</u> | <u>**Description**</u> |
| 99.1 | [Dyadic International Press Release Dated January 4, 2023](ex_460691.htm) |
| 99.2 | [Dyadic International Presentation, "Next Generation Proteins for World Health", dated January 4, 2023](ex_460347.htm) |
| 104 | Cover page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 4, 2023

---

| | |
|:---|:---|
| **Dyadic International, Inc.** | **Dyadic International, Inc.** |
| **By:** | /s/ Mark A. Emalfarb |
| **Name:** | Mark A. Emalfarb |
| **Title:** | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![ex_460691img001.jpg](ex_460691img001.jpg)

**Dyadic to Attend J.P. Morgan 41st Annual Healthcare Conference**

***Dyadic's executive management to attend the J.P. Morgan 41st Annual Healthcare Conference and the 6th Annual BFC Global Healthcare BD and Investment Conference from January 8-12 in San Francisco, CA USA***

**JUPITER, FL / GLOBE NEWSWIRE / January 4, 2023,** Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet clinical needs for effective and affordable biopharmaceutical products for human and animal health, today announces that its senior executive management will attend the <u>J.P. Morgan 41st Annual Healthcare Conference</u> in San Francisco, CA. Dyadic's founder and CEO, Mark Emalfarb will be making a corporate presentation at 4:00 PM PT on January 8, 2023 at the <u>6th Annual BFC Global Healthcare BD and Investment Conference</u>, San Francisco, CA. Mr. Emalfarb will also be participating on the opening panel, which is scheduled at 9:15-10:15 AM PT.

The corporate presentation will focus on the recent advancements Dyadic has made with its C1-cell protein expression platform including the initiation of its first in human Phase 1 program for an antigen expressed in the C1 platform, with the trial expected to begin later this month. At the October 2022 World Vaccine Conference, Dyadic shared data demonstrating the capability of its C1 protein production platform to produce ferritin nanoparticle vaccines for COVID-19. At the BFC conference, Mr. Emalfarb will be discussing the encouraging intranasal and intramuscular animal data from one of the C1 produced COVID-19 ferritin nanoparticle vaccine candidates which generated much higher neutralizing antibodies compared to non-ferritin nanoparticle vaccines. The importance of these and other ongoing animal studies of C1 produced vaccine candidates builds upon other data from third party pre-clinical and clinical trials conducted by Walter Reed Medical Center, Duke University, and other widely respected institutions. These studies demonstrated the potential for nanoparticle vaccines to elicit potent immune response with the potential to provide broader more durable protection against SARS-CoV-2 as well as certain variants of concern. Dyadic will continue to leverage its scientific advancements, pre-clinical data, and upcoming Phase 1 data to expand the adoption of the C1 platform for speeding development, lowering production costs, and improving the performance of biologic vaccines and drugs, at flexible commercial scales, for the human and animal health markets. We expect these efforts to help facilitate health equity in emerging as well as developed countries across the globe.

Mr. Emalfarb will be joined by Chief Business Officer, Joe Hazelton, and they will be available for 1:1 meetings during the conferences in San Francisco. Interested parties can request meetings by contacting <u>ir@dyadic.com</u>.

------

**About Dyadic International, Inc.**

Dyadic International, Inc. is a global biotechnology company committed to building disruptive microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products for human and animal health.

Dyadic's lead technology, its C1-cell gene expression and protein production platform, is based on the highly productive and scalable industrially proven fungus *Thermothelomyces heterothallica* (*formerly Myceliophthora thermophila).* C1-cell gene expression and protein production platform is currently used to speed development, lower production costs, and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets.

Dyadic is also developing the Dapibus™ filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, such as food, nutrition, and wellness.

With a passion to enable our partners and collaborators to develop effective preventative and therapeutic treatments in both developed and emerging countries, Dyadic is building an active pipeline by advancing its proprietary microbial platform technologies, including our lead product DYAI-100 COVID-19 booster vaccine candidate, as well as other biologic vaccines, antibodies, and other biological products.

To learn more about Dyadic and our commitment to helping bring vaccines and other biologic products to market faster, in greater volumes and at lower cost, please visit <u>www.dyadic.com</u>.

**Safe Harbor Regarding Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic International's expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, such as the success of our clinical trial our research projects and third-party collaborations, as well as the availability of necessary funding. Actual events or results may differ materially from those in the forward-looking statements because of various important factors, including those described in the Company's most recent filings with the SEC. Dyadic assumes no obligation to update publicly any such forward-looking statements, whether because of new information, future events or otherwise. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled "Risk Factors" in Dyadic's annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic's periodic filings with the SEC, which are accessible on the SEC's website and at <u>www.dyadic.com</u>.

------

**Contact:**

Dyadic International, Inc.

Ping W. Rawson

Chief Financial Officer

561-743-8333

Email: <u>ir@dyadic.com</u>

## Exhibit 99.2

**Exhibit 99.2**

![a01.jpg](a01.jpg)

------

![a02.jpg](a02.jpg)

------

![a03.jpg](a03.jpg)

------

![a04.jpg](a04.jpg)

------

![a05.jpg](a05.jpg)

------

![a06.jpg](a06.jpg)

------

![a07.jpg](a07.jpg)

------

![a08.jpg](a08.jpg)

------

![a09.jpg](a09.jpg)

------

![a10.jpg](a10.jpg)

------

![a11.jpg](a11.jpg)

------

![a12.jpg](a12.jpg)

------

![a13.jpg](a13.jpg)

------

![a14.jpg](a14.jpg)

------

![a15.jpg](a15.jpg)

------

![a16.jpg](a16.jpg)

------

![a17.jpg](a17.jpg)

------

![a18.jpg](a18.jpg)

------

![a19.jpg](a19.jpg)

------

![a20.jpg](a20.jpg)

------

![a21.jpg](a21.jpg)

------

![a22.jpg](a22.jpg)

------

![a23.jpg](a23.jpg)

------

![a24.jpg](a24.jpg)

------

![a25.jpg](a25.jpg)

------

![a26.jpg](a26.jpg)

------

![a27.jpg](a27.jpg)

------

![a28.jpg](a28.jpg)

------

![a29.jpg](a29.jpg)

------

![a30.jpg](a30.jpg)

------

![a31.jpg](a31.jpg)

------

![a32.jpg](a32.jpg)

------

![a33.jpg](a33.jpg)

------

![a34.jpg](a34.jpg)

------

![a35.jpg](a35.jpg)

------

![a36.jpg](a36.jpg)

------

![a37.jpg](a37.jpg)

------

![a38.jpg](a38.jpg)

------

![a39.jpg](a39.jpg)